What Is Psoriasis?
Psoriasis is a genetically programmed inflammatory disease that primarily affects the skin in about 3% of individuals in the United States. Psoriasis is characterized by skin cells that multiply up to 10 times faster than normal. When these cells reach the surface and die, raised, red plaques covered with white scales form. Psoriasis begins as a small scaling papule. When multiple papules coalesce, they form scaling plaques. These plaques tend to occur in the scalp, elbows, and knees.
Although psoriatic plaques can be limited to only a few small areas, the condition can involve widespread areas of skin anywhere on the body. Psoriasis symptoms vary depending on the type of psoriasis you have. Common psoriasis symptoms can include the following:
Plaque psoriasis is the most common type of psoriasis and it gets its name from the plaques that build up on the skin. There tend to be well-defined patches of red raised skin that can appear on any area of the skin, but the knees, elbows, scalp, trunk, and nails are the most common locations. There is also a flaky, white build up on top of the plaques, called scales. Possible plaque psoriasis symptoms include skin pain, itching, and cracking.
There are plenty of over-the-counter products that are effective in the treatment of plaque psoriasis. 1% hydrocortisone cream is a topical steroid that can suppress mild disease and preparations containing tar are effective in treating plaque psoriasis.
Scalp psoriasis is a common skin disorder that makes raised, reddish, often scaly patches. Scalp psoriasis can affect your whole scalp, or just pop up as one patch. This type of psoriasis can even spread to the forehead, the back of the neck, or behind the ears. Scalp psoriasis symptoms may include only slight, fine scaling. Moderate to severe scalp psoriasis symptoms may include dandruff-like flaking, dry scalp, and hair loss. Scalp psoriasis does not directly cause hair loss, but stress and excess scratching or picking of the scalp may result in hair loss.
Scalp psoriasis can be treated with medicated shampoos, creams, gels, oils, ointments, and soaps. Salicylic acid and coal tar are two medications in over-the-counter products that help treat scalp psoriasis. Steroid injections and phototherapy may help treat mild scalp psoriasis. Biologics are the latest class of medications that can also help treat severe scalp psoriasis.
Guttate psoriasis looks like small, pink dots or drops on the skin. The word guttate is from the Latin word gutta, meaning drop. There tends to be fine scales with guttate psoriasis that is finer than the scales in plaque psoriasis. Guttate psoriasis is typically triggered by streptococcal (strep throat) and the outbreak will usually occur two to three weeks after having strep throat.
Guttate psoriasis tends to go away after a few weeks without treatment. Moisturizers can be used to soften the skin. If there is a history of psoriasis, a doctor may take a throat culture to determine if strep throat is present. If the throat culture shows that streptococcal is present, a doctor may prescribe antibiotics.
Many patients with psoriasis have abnormal nails. Psoriatic nails often have a horizontal white or yellow margin at the tip of the nail called distal onycholysis because the nail is lifted away from the skin. There can often be small pits in the nail plate, and the nail is often yellow and crumbly.
The same treatment for skin psoriasis is beneficial for nail psoriasis. However, since nails grow slow, it may take a while for improvements to be evident. Nail psoriasis can be treated with phototherapy, systemic therapy (medications that spread throughout the body), and steroids (cream or injection). If medications do not improve the condition of nail psoriasis, a doctor may surgically remove the nail.
Psoriasis can be associated with a destructive arthritis called psoriatic arthritis. Damage can be serious enough to permanently damage the affected joints. Prevention of joint damage in such cases is very important.
Psoriatic arthritis is a chronic disease characterized by a form of inflammation of the skin and joints. About 15%-25% of patients with psoriasis also develop an inflammation of their joints. Psoriatic arthritis is a systemic rheumatic disease that can not only cause inflammation of the skin, but in the eyes, heart, kidneys, and lungs as well. Currently, the cause of psoriatic arthritis is unknown, but a combination of genetic, immune, and environmental facts is likely involved.
Typically, a patient will have psoriasis months or years before they develop psoriatic arthritis. Psoriatic arthritis usually involves the knees, ankles, and joints in the feet. There may also be a loss of range of motion of the involved joints as well as joint stiffness. Psoriatic arthritis can also cause inflammation of the spine and the sacrum, which causes pain and stiffness in the low back, buttocks, neck, and upper back.
Treatment for psoriatic arthritis generally involves anti-inflammatory medications and exercise. It is important to stretch or take a hot shower before exercise in order to relax the muscles. Ice application after exercise can help minimize soreness and inflammation. Nonsteroidal anti-inflammatory drugs may also reduce joint inflammation, pain, and stiffness.
It is now clear that there is a genetic basis for psoriasis. This hereditary predisposition is necessary before the disease can be triggered by environmental factors. White blood cells called T-cells mediate the development of the psoriatic plaques that are present in the skin. When someone has psoriasis, their body is unable to offer protection from invaders. Instead, inflammation is promoted and skin cells are on overdrive. When cell growth is increased, old skin cells pile up instead of flaking off, causing psoriasis to occur. Currently, most experts conclude that environmental, genetic and immunologic factors interact to cause the disease.
If you have the genetic basis of psoriasis, a trigger can cause psoriasis to flare up. The following are triggers that may set off one's psoriasis:
No, psoriasis is not contagious. People used to believe that psoriasis was the same as leprosy, but that is not the case. You cannot get psoriasis by touching, kissing, or having sex with someone who has psoriasis. People get psoriasis because of their genes, not their hygiene, diet, lifestyle, or any other habits.
Psoriasis is often diagnosed or at least suspected on the basis of its appearance and distribution. However, psoriasis may resemble eczema or other skin diseases and further tests may be required. It may be necessary to remove a small piece of skin (a biopsy) and have it examined by a pathologist to confirm the diagnosis. If there are joint symptoms, X-rays and other laboratory tests may be in order. Psoriasis cannot be cured, but like many other medical conditions, it is controllable with treatment. Your doctor may have you seen by a consultant such as a dermatologist, rheumatologist or immunologist to help diagnose and treat your form of psoriasis.
Since psoriasis mainly affects the skin, topical treatments are very useful because they are relatively safe, fairly effective, and can be applied directly to the affected skin. They take the form of lotions, foams, creams, ointments, gels, and shampoos. They include topical steroids, tar preparations, and calcium- modulating drugs. The precise drug used and the form in which it is delivered depends on the areas involved. In widespread disease in patients with more than 10% of the body surface involved, it may not be practical to use topical medication alone.
For more extensive psoriasis, a useful option is ultraviolet (UV) light exposure. UV light can treat large areas of skin with few side effects, if performed in the physician's office. It should be kept in mind that all UV light causes mutational events, which can lead to skin cancer. At this time, the most popular type of UV light for psoriasis is called narrow-band UVB. Only a small portion of the UV light spectrum is used, which seems to be particularly beneficial for psoriasis and may be less carcinogenic. This UVB is quite different from the UVA, the wavelength available in tanning salons, which is not effective in psoriasis. Phototherapy can be used alone or with medications when treating psoriasis.
Excimer lasers or pulsed dye lasers are used in laser therapy. A pulsed dye laser will create a concentrated beam of yellow light. When this light hits the skin, it converts to heat. The heat then destroys the extra blood vessels in the skin that contribute to psoriasis. Excimer lasers will deliver ultraviolet light to localized areas of the skin that help treat psoriasis. These lasers produce UV light in wavelengths similar to narrow-band UVB. Laser therapy uses intense doses of laser light to help control areas of mild to moderate psoriasis without damaging surrounding healthy skin. These can be quite effective for small plaques of psoriasis, but since only small areas of skin can be treated at once, they are not practical for extensive disease.
There are a variety of drugs administered systemically that are useful in controlling psoriasis. As a generalization, most oral medications act by targeting portions of the immune system. The only exception currently is a drug called acitretin (Soriatane), which is structurally similar to vitamin A. Since the immune system is necessary in order to survive, systemic treatments do have a downside. Drugs like methotrexate and cyclosporine are administered orally and can affect the liver, kidney, and bone marrow. A new oral medication recently approved for treatment of psoriasis is called Otezla (apremilast). Otezla selectively targets molecules inside immune cells and adjusts (reduces) the processes of inflammation within the cell, which in turn helps treat psoriasis. This drug appears to be considerably safer that most of its predecessors but is also quite expensive.
A new class of drugs has recently been developed called biologics; they're called biologics because living cells synthesize them. Since these drugs are proteins, they cannot be administered orally and must be given by injection through the skin or by an intravenous infusion. This treatment is recommended in patients with moderate to severe psoriasis. These drugs target the immune response that leads to the rapid skin cell growth of psoriasis. This seems to have increased their safety profile as well as their effectiveness when compared to older drugs. On the other hand, they are quite expensive costing up to $30,000 a year.
There are many home remedies that can be used in the treatment of psoriasis. It is very important to keep the skin moist to avoid dryness. Petroleum jelly, shortening, or olive oil can be used as a moisturizer. Take fewer showers and baths to avoid stripping the skin of its natural oils. Adding salts, oil, or finely ground oatmeal to the bath can soothe the skin. Heliotherapy (medicinal sunbathing) can be effective in controlling psoriasis. There is also evidence that increased body mass is associated with psoriasis and that heavier individuals are more difficult to treat.
At the edge of Israel's Dead Sea, there are a group of resorts that cater to psoriasis patients by offering a combination of graded solar exposure and the application of crude coal tar along with a spa-like experience. The Dead Sea is the lowest point on earth, more than 400 meters below sea level. Once the sun's rays pass through the haze, the harmful ultraviolet rays are filtered out and the remaining rays are highly effective in treating psoriasis. For those with the time and the money, this is a reasonable alternative to standard medical treatment.
Although there is no doubt that psoriasis is a potent inducer of stress, the evidence that stress causes psoriasis is sparse. However, stress can make psoriasis worse, and psoriasis can make one stressed. Dealing with stress with or without psoriasis is a challenge for most people living in the 21st century. The following are tips to reduce stress:
Not only are the physical effects of psoriasis frustrating, but the emotional effects of psoriasis can be much worse. Psoriasis may cause your relationships to change and people may treat you differently. Unfortunately, this may lead to stress, which then leads to worsening psoriasis. A doctor may prescribe antidepressant medications if psoriasis is diminishing your quality of life. Support groups can also help you cope with psoriasis by talking to other people who are suffering from the same disease.
Fall and winter may bring shorter days, colder temperatures, and dry air. These can all lead to worsening psoriasis symptoms. The sun's ultraviolet light hinders the rapid growth of skin cells that is characteristic of psoriasis. Therefore, spending less time in the sun may cause psoriasis symptoms to flare. The dry weather may remove moisture in your skin so it is important to use moisturizer and/or a humidifier at home.
There are many different remedies that may ease psoriasis symptoms. The following is a partial list of alternative medicine to help treat psoriasis:
Consult your doctor before trying new medications.
There is plenty of evidence that extensive psoriasis can have a very significant negative effect on a patient's self-image and emotions. This is especially true in social situations, although all aspects of life can be disturbed. Inverse psoriasis, which affects the genital skin, and scalp psoriasis can be particularly troubling. Psoriasis affecting the hands may make it impossible to interact normally with others. It is important to remember that there are ways to manage and treat psoriasis flares. It may seem as if one's quality of life has diminished, but there are many organizations that offer support to psoriasis patients. The National Psoriasis Foundation is an excellent source of accurate information as well as emotional support for afflicted patients.
IMAGES PROVIDED BY:
REFERENCES:
2005-2016 WebMD, LLC. All rights reserved.
More here:
Psoriasis Types, Images, Treatments - onhealth.com
- Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment ... - Dermatology Times - April 18th, 2024 [April 18th, 2024]
- Psoriasis Patients with Arthralgia At Increased Risk of Psoriatic Arthritis Development - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Diagnosing Psoriatic Arthritis for the Dermatologist: Guidance From the Experts - Medscape - April 18th, 2024 [April 18th, 2024]
- Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg - MD Magazine - April 18th, 2024 [April 18th, 2024]
- The Impact of Pediatric Plaque Psoriasis on Children and Caregivers - HMP Global Learning Network - April 18th, 2024 [April 18th, 2024]
- Guselkumab Led to Improvements Over Several Psoriatic Arthritis Disease Domains - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Dual Diagnosing and Managing Psoriasis and Psoriatic Arthritis - The Dermatologist - April 18th, 2024 [April 18th, 2024]
- Etanercept Effective for Psoriasis, Rheumatic Disease Among Patients Extending Treatment After 12-Weeks - MD Magazine - February 9th, 2024 [February 9th, 2024]
- High Response Rates in Psoriasis With Oral IL-23 Inhibitor - Medpage Today - February 9th, 2024 [February 9th, 2024]
- Psoriasis and eczema have complex causes and consequences that researchers are seeking to uncover - Medical Xpress - February 9th, 2024 [February 9th, 2024]
- New Hope in Treatment of Plaque Psoriasis: Study Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- No Difference in Psoriasis Immune Response Despite Switch Between AVT02, Adalimumab - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Breakthrough in Psoriasis Treatment: JNJ-77242113 Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from Phase II Trial of Oral Interleukin Inhibitor for Psoriasis Treatment - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from the FRONTIER 1 Trial - An Exploration of JNJ-77242113 in the Treatment of Moderate-to ... - Medriva - February 9th, 2024 [February 9th, 2024]
- Personal Experience with Psoriatic Arthritis and Atopic Dermatitis - Medriva - February 9th, 2024 [February 9th, 2024]
- Rising Cost of Stelara: Impact on Patients and Johnson & Johnson's Market Performance - Medriva - February 9th, 2024 [February 9th, 2024]
- Global Psoriatic Arthritis (PsA) Treatment Market to achieve a remarkable US$ 15.6 Billion by 2028, - PharmiWeb.com - February 9th, 2024 [February 9th, 2024]
- Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter - May 31st, 2023 [May 31st, 2023]
- Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Janssen Announces Positive Results From Guselkumab Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Early Intervention with Secukinumab May Be Effective for Patients ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Scratching the itch, Lynk Pharmaceuticals trialling ointment for ... - OutSourcing-Pharma.com - May 31st, 2023 [May 31st, 2023]
- Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- For Patients With Birthmarks, Psychosocial Interventions Improved ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Nalbuphine ER Tablets Show Promise as Cough Therapy in ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- selectION reports results from SAD stage of si-544 Phase Ib trial - Clinical Trials Arena - May 31st, 2023 [May 31st, 2023]
- No Link Observed Between Gastrointestinal Tract Surgery and New ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Lynk doses first cohort in Phase Ib trial of psoriasis therapy - Clinical Trials Arena - May 30th, 2023 [May 30th, 2023]
- Metabolic Inflammation Contributes to Depression in Psoriatic Disease - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Encouraging Diversity and Inclusion for Patients With Psoriatic ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- The Weekly Roundup: May 22-26 - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Pediatric Psoriasis Market: A Study of the Industry's Key Applications ... - The Navajo Post - May 30th, 2023 [May 30th, 2023]
- Phototherapy Lamps Market are set to witness a CAGR of 5.8 ... - Digital Journal - May 30th, 2023 [May 30th, 2023]
- Celltrion seeks approval for Stelara biosimilar in EU - The Investor - May 30th, 2023 [May 30th, 2023]
- Peter Marinkovich, MD: FDA Approval of B-VEC Gene Therapy for ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Tildrakizumab Linked With HRQOL Improvement in Psoriasis in a Real-World Setting - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Clinical Utility of Deucravacitinib for the Management of Moderate to ... - Dove Medical Press - May 18th, 2023 [May 18th, 2023]
- Covid-19 and Psoriasis: Is there a link? - Dunya News - May 18th, 2023 [May 18th, 2023]
- Improvement Needed in Study Interventions to Better Skin Self ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Adam Friedman, MD: Addressing Disparities in Care for Patients ... - MD Magazine - May 18th, 2023 [May 18th, 2023]
- Early-Infancy Meningitis Infection Linked With Increased Risk of ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- NOVN: Counting Down to PDUFA - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR ... - Future Market Insights - May 18th, 2023 [May 18th, 2023]
- New campaign raises awareness of topical steroid withdrawal - Professional Beauty - May 18th, 2023 [May 18th, 2023]
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in... - February 2nd, 2023 [February 2nd, 2023]
- EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K) -... - February 2nd, 2023 [February 2nd, 2023]
- 12 Ways to Treat Psoriasis at Home - Healthline - January 22nd, 2023 [January 22nd, 2023]
- DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value - Forbes - January 19th, 2023 [January 19th, 2023]
- Types of Psoriasis: Pictures, Symptoms and Treatments - Healthline - December 18th, 2022 [December 18th, 2022]
- Psoriasis Pathogenesis and Treatment - PMC - PubMed Central (PMC) - November 23rd, 2022 [November 23rd, 2022]
- Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? - November 23rd, 2022 [November 23rd, 2022]
- Im a Dermatologist and These 7 Things Could Be Making Your Psoriasis Worse - Well+Good - October 19th, 2022 [October 19th, 2022]
- 'Worst time of the year for me to be covered in scabs': Amber Heard's Alleged Ex Cara Delevingne Revealed Her Psoriasis Struggle Made Kate Moss Scream... - October 19th, 2022 [October 19th, 2022]
- Psoriasis: What It Is, Symptoms, Causes, Types & Treatment - October 17th, 2022 [October 17th, 2022]
- What is psoriasis and which foods ease symptoms? - Evening Standard - October 17th, 2022 [October 17th, 2022]
- Chronic inflammatory diseases: what they are - Emergency Live International - October 17th, 2022 [October 17th, 2022]
- How remote care can deliver a step change in treatment for inflammatory skin conditions - PoliticsHome - October 17th, 2022 [October 17th, 2022]
- Probiotics Supplementation may Improve Symptoms of Hyperuricemia and Gout - Rheumatology Network - October 15th, 2022 [October 15th, 2022]
- Psoriasis Pathogenesis and Treatment - PubMed - October 2nd, 2022 [October 2nd, 2022]
- Best and Worst Drinks for Psoriasis - Everyday Health - October 2nd, 2022 [October 2nd, 2022]
- These Are the 10 Most Common Chronic Skin Conditionsand the Most Important Facts to Know About Them - Parade Magazine - October 2nd, 2022 [October 2nd, 2022]
- Survey Addresses Concerns Regarding Reproductive Healthcare Communication in Women with RA, PsA - Rheumatology Network - October 2nd, 2022 [October 2nd, 2022]
- Psoriasis Types, Symptoms & Causes | NIAMS - September 29th, 2022 [September 29th, 2022]
- What Is Psoriasis And Can It Be Treated? - Forbes - September 29th, 2022 [September 29th, 2022]
- Plaque Psoriasis Treated With Tildrakizumab Shown to be Effective in Real-World Settings - MD Magazine - September 29th, 2022 [September 29th, 2022]
- Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis - Business Wire - September 29th, 2022 [September 29th, 2022]
- 15 Items That Will Make Your Life With Psoriatic Arthritis Easier - BlackDoctor.Org - September 29th, 2022 [September 29th, 2022]
- Types of Psoriasis and Their Effects on the Immune System - Cureus - September 27th, 2022 [September 27th, 2022]
- MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis - BioSpace - September 27th, 2022 [September 27th, 2022]
- How diversity and inclusion continues to be incorporated in dermatology - PMLiVE - September 27th, 2022 [September 27th, 2022]
- Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp A - Benzinga - September 27th, 2022 [September 27th, 2022]
- Psoriasis Treatment Market Size to Hit USD 51.24 Bn by 2030 - GlobeNewswire - August 15th, 2022 [August 15th, 2022]
- Ventyx Sees Initiation Of Mid-Stage Psoriasis Study In Q4 2022 Following Positive Data From Initial-Stage - Benzinga - August 15th, 2022 [August 15th, 2022]